Introduction
============

Discovered in 2001, resistin (RES) is a cysteine-rich protein of molecular weight 12.5 kDa and structurally similar to cytokines.[@b1-dmso-12-043],[@b2-dmso-12-043] RES is an adipokine, in mice it is mainly expressed by adipocytes. Its major sources in humans are monocytes and macrophages.[@b2-dmso-12-043]--[@b4-dmso-12-043] In uremic patients, serum RES concentrations are elevated as compared to individuals with normal renal function.[@b5-dmso-12-043] It has not been concluded whether higher RES concentration is secondary to reduced renal clearance or reflects chronic inflammation.[@b6-dmso-12-043]--[@b8-dmso-12-043] Hemodialysis does not eliminate RES as expected for its molecular size.[@b2-dmso-12-043] RES is an independent biomarker associated with all-cause and cardiovascular mortality in senile patients, hypertensive individuals, and at early stages of chronic kidney disease.[@b9-dmso-12-043],[@b10-dmso-12-043] The correlation between RES concentration and metabolic indicators in individuals with normal renal function remains unexplained.[@b11-dmso-12-043] Despite its name, the effect of this adipokine on the development of insulin resistance in humans has never been explicitly demonstrated.[@b12-dmso-12-043],[@b13-dmso-12-043] There have also been some contradictory reports on the relation of RES with obesity, insulin resistance, and type 2 diabetes.[@b4-dmso-12-043],[@b14-dmso-12-043]--[@b16-dmso-12-043] Like uremia, obesity is a chronic inflammatory condition. Although low shares of human RES originate from fat cells, its concentration correlates with the body mass and responds to weight changes.[@b17-dmso-12-043],[@b18-dmso-12-043]

In hemodialyzed (HD) patients, the serum RES concentration is increased, but it does not correlate with insulin resistance,[@b19-dmso-12-043] and hemodialysis improves insulin sensitivity and decreased insulin clearance.[@b20-dmso-12-043]--[@b22-dmso-12-043] In healthy subjects, the association between RES and inflammatory markers has been confirmed.[@b23-dmso-12-043] Similarly, in HD patients, a relationship between RES and concentrations of high sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and the number of leucocytes has been observed.[@b24-dmso-12-043],[@b25-dmso-12-043]

Regular physical exercise reduces mortality and morbidity of many diseases and demonstrates a cardio-protective effect.[@b26-dmso-12-043] However, what seems most important is the anti-inflammatory effect of regular physical exercise caused, among others, by the secretion of anti-inflammatory cytokines by the muscles.[@b26-dmso-12-043]--[@b28-dmso-12-043] Exercise training intervention in individuals with normal renal function reduces RES, leptin, IL-6, and homocysteine (Hcy) concentrations especially in the overweight or obese population.[@b23-dmso-12-043]

Despite numerous reports indicating the anti-inflammatory effect of physical exercise in chronic conditions,[@b26-dmso-12-043],[@b29-dmso-12-043],[@b30-dmso-12-043] including early stage of chronic kidney disease (CKD),[@b27-dmso-12-043] the relationship between regular exercise and inflammation indices in HD patients remains unclear.[@b31-dmso-12-043]

The effect of enhanced physical activity on reduced RES concentrations in healthy individuals has been well documented.[@b32-dmso-12-043] However, no studies have been conducted to define the role of physical activity in RES concentrations in HD patients.

Metabolic syndrome (MS) is a recognized and proven risk factor for cardiovascular disease.[@b33-dmso-12-043] Uremia itself is a very strong cardiovascular risk factor, and one wonders whether the presence of MS adds to increasing the risk. It is possible that the MS interferes with physiologically observed responses to physical activity program. The phenomenon of reverse epidemiology occurs in uremic patients.[@b34-dmso-12-043],[@b35-dmso-12-043] Higher body mass index (BMI) correlates with lower all-cause and cardiovascular mortality.[@b33-dmso-12-043] We hypothesized that the response of HD patients to exercise training intervention may vary depending on the presence or absence of the MS.

The aim of the study was to investigate a metabolic and inflammatory response, with a special focus on RES, to the 4-week supervised rehabilitation program including individualized aerobic exercises in end-stage renal disease patients treated with hemodialysis, with or without MS.

Subjects and methods
====================

This prospective interventional study comprised 28 consecutive patients of a dialysis center (study group HD), aged 56.9±13.3 years ($\overline{x} \pm \text{SD}$; in the range from 25 to 75 years), 57% women, who were treated with hemodialysis for 50.6±73.4 months (in the range from 5 to 272 months) and fulfilled the criteria for participation and completed the program. These subjects were recruited at the dialysis center in Katowice, Poland. A control group (C) comprised 30 consecutive patients of the rehabilitation day ward, aged 61.5±8.3 years ($\overline{x} \pm \text{SD}$; in the range from 37 to 76 years), 50% women, who fulfilled the criteria for participation and completed the program. These subjects were recruited at the Department of Rehabilitation at University Hospital (No. 7 SUM, Upper Silesian Medical Center, Katowice, Poland; [Figure 1](#f1-dmso-12-043){ref-type="fig"}).

Written informed consent was obtained from each subject after the aim of the study, protocol, and risks were presented and explained.

Inclusion criteria involved: age \>18 years, end-stage renal failure with the hemodialysis treatment duration \>3 months (for the study group) or normal kidney function (assessed by eGFR, general urinalysis, 24-hours albumin excretion, and renal ultrasound results) -- for the control group, capacity to perform low-level intensity exercise, and written informed consent for participation in the study.

Exclusion criteria included: a systemic rheumatic disease, cancer, conditions preventing/inability to perform low-level intensity exercise (New York Heart Association class IV heart failure, advanced mobility disorders), history of clinically overt infection during past 3 months, immunosuppressive therapy, and pregnancy ([Figure 1](#f1-dmso-12-043){ref-type="fig"}).

All subjects were further divided according to the MS. Diagnosis of MS was based on the presence of at least three out of five distinct, clinically relevant cardio-metabolic risk factors for the European population, that is, waist circumference, WC: female ≥80 cm, male ≥94 cm; fasting triglyceride concentration, TG ≥150 mg/dL or treatment of hypertriglyceridemia; fasting high-density lipoprotein cholesterol: female \<50 mg/dL, male \<40 mg/dL or use of concentration-increasing drugs; systolic blood pressure, sSBP ≥130 mmHg or diastolic blood pressure, DBP ≥85 mmHg or use of antihypertensive drugs; fasting serum glucose concentration ≥100 mg/dL or use of medication for hyperglycemia, according to the International Diabetes Federation, National Heart, Lung, and Blood Institute, and American Heart Association.[@b36-dmso-12-043]

Fourteen patients of the study group met criteria of MS (HD-MS subgroup) while 14 others did not (HD-non-MS \[nMS\] subgroup). Also, 13 individuals of the control group met these criteria (C-MS subgroup) while 17 subjects did not (C-nMS subgroup).

The study was approved by the Bioethical Committee of the Medical University of Silesia in Katowice (resolution no. KNW/0022/KB1/44/II/06/14/17) and was carried out according to the Declaration of Helsinki regarding human studies.

Measurements
------------

The patients were evaluated for their body weight, height, BMI and waist circumference, Charlson comorbidity index (CCI) and cardiopulmonary exercise testing (CPET). CPET is an exercise test with analysis of breathing gases. Ventilation and gas exchange were measured breath-by-breath with an automated metabolic measurement system (ZAN 680). The CPET was performed on a treadmill ergometer (TM425). Before each test, the device was calibrated with standard calibration gases. The heart rate, SBP, and DBP at rest, the end of each stage, peak exercise, and during recovery were assessed.

Fasting blood samples (at least 12 hours after the last meal) were taken between 6:00 and 7:00 am on the post-dialysis day before initiation of the program and on the day next to the completion of the of the 4-week physical activity program. Post-dialysis day refers to another day without hemodialysis.

Laboratory tests included blood hemoglobin concentration, leucocytes and lymphocytes count, and HbA1c percentage, as well as hs-CRP, albumin, glucose, insulin, creatinine, PTH, sodium, potassium, and phosphorous serum concentrations. Homeostasis Model Assessment (HOMA), according to the formula: fasting state glycaemia (mmol/L) × fasting insulin (µIU/mL)/22.5, was used to quantify insulin resistance. We derived eGFR from serum creatinine using the Chronic Kidney Disease Epidemiology Collaboration equation.[@b37-dmso-12-043]

Kt/V (natural logarithm of the ratio of urea concentrations before and after dialysis) was used to quantify the adequacy of dialysis.

Serum samples were collected at −80°C for cytokine and hormonal tests. Serum concentrations of RES, adiponectin, cystatin C, erythropoietin, TNF-α, IL-6, transforming growth factor beta 1 (TGF-β1), and plasminogen activator inhibitor-1 (PAI-1) were assessed with the use of ELISA tests, leptin -- radio-immuno-assay test and Hcy -- with the use of the lumino-immuno-assay test.

Rehabilitation program
----------------------

Initial rehabilitation assessment including anamnesis, physical and anthropometric examination, and functional capacity assessment was performed in each subject. Treadmill stress test according to the modified Bruce protocol with continuous gas analysis was used to assess ventilatory anaerobic threshold (VAT). The anaerobic threshold (VAT) was estimated using the V-slope method.[@b38-dmso-12-043] Cardiac rehabilitation exercise programs were used as the base of rehabilitation program. Individualized supervised rehabilitation program based on physiotherapy was provided to each subject for 4 weeks, 6 days a week, 2 hours a day. A regular physical activity program was also carried out on dialysis days. Hemodialysis sessions were conducted in the afternoon hours.

This program included 20--40 minute (25±10 minutes) of aerobic endurance training (AET) -- walking, treadmill walking, forward and back walking, and cycling on stationary ergometers. Intensity of exercise in patients after CPET was about 10% below VAT. Every time, the intensity of exercise was closed to VAT. In patients without CPET (15.5%), the intensity of AET was closed between 40% and 60% of heart rate reserve. During all sessions of AET the rating of perceived exertion based on Borg 6--20 scale was below 13.[@b39-dmso-12-043] This exercise was complemented with isometric exercises, free active exercises, balance and coordination exercises, active breathing exercises, exercises in part or full unloading, manual therapy, medical massage, relaxation exercises, transcutaneous electrical nerve stimulation, laser therapy, ultrasound and light therapy, and magnetic field therapy. All participants accomplished at least 90% of the prescribed training sessions.

Statistics
----------

Statistical analysis was carried out by using Statistica 13.1 (Stat Soft, Inc., Tulsa, OK, USA). Results are presented as mean and standard deviation $(\overline{x} \pm \text{SD})$ or as medians. The Student's paired *t*-test or the Wilcoxon test was used to compare the variables before and after rehabilitation program. The Student's independent *t*-test was used to compare HD group and C group. Mann--Whitney *U* test was applied for non-parametric variables. Relationships between variables were determined with the Spearman rank correlation test. The level of significance was set at *P*\<0.05.

Ethics statement
----------------

The results of scientific studies are anonymized and will be stored as such in an electronic form in a structured Statistica format on the premises of the facility conducting the study. The data will be stored for a period of 15 years. If requested, it can be made available in an anonymized form to the publisher within the scope of the presented work. Personal data related to this research are kept on the premises of the medical facility where the studies have been conducted. The data are subject to provisions on data protection in accordance with the law (Patients' Rights and Patients' Rights Ombudsman Article 26 section 4).

Results
=======

Comparison of HD group and C group
----------------------------------

The most prevalent causes of end-stage renal failure were: glomerulonephritis (25.1%), diabetic renal disease (21.4%), and hypertensive nephropathy (21.4%). The mean CCI in the HD and C groups were 4.5±3.6 and 1.03±0.61, respectively (*P*\<0.001). The vascular access was through an arterio-venous (AV) fistula in 24 patients (85.6%) or through AV graft or dialysis catheter. Bicarbonate dialysis sessions lasted 4--4.5 hours and was performed 3--5 times a week using of high-flux dialysis machines. The dialysis fluid flow rate was 500 mL/min and blood flow 250--350 mL/min. Dialysis adequacy index (Kt/V) was 1.41±0.23. HD and C groups were demographically and anthropometrically comparable, showing no significant differences in age, sex, and BMI. HD group compared to C group showed significantly higher serum concentrations of creatinine, potassium RES, leptin, cystatin C, hs-CRP, TNF-α, Hcy, WBC, phosphorus, and PTH. Individuals with normal renal function had higher hemoglobin, glucose, and albumin concentration ([Table 1](#t1-dmso-12-043){ref-type="table"}).

Comparison of HD-MS subgroup and HD-nMS subgroup
------------------------------------------------

HD-MS patients showed significantly higher serum leptin, PAI-1, and phosphorus compared to HD-nMS subgroup (40.23±31.99 vs 19.60±31.78 ng/mL; *P*=0.01 and 52.24±24.14 vs 34.63±18.01 ng/mL; *P*=0.04 and 5.55±1.00 vs 4.92±1.45 mg/dL; *P*=0.049, respectively). HD-MS subgroup to HD-nMS subgroup showed significantly higher HbA1c (6.19±1.55% vs 4.97%±0.80%; *P*=0.01). Other study parameters did not differ significantly between the subgroups with and without the MS ([Table 2](#t2-dmso-12-043){ref-type="table"}).

Comparison of C-MS subgroup and C-nMS subgroup
----------------------------------------------

C-MS participants had higher leptin and TNF-α concentrations also number of leucocytes than the C-nMS subgroup (14.78±13.17 vs 8.10±9.22 ng/mL; *P*=0.04, 9.22±2.55 vs 6.70±2.17 pg/mL; *P*=0.007, 6.93±2.51 vs 5.31±1.23×10³/µL; *P*=0.03, respectively). C-MS subgroup compared to C-nMS subgroup showed significantly higher HbA1c (6.39±1.34% vs 5.37±0.75%; *P*=0.02). Other study parameters did not differ significantly between the subgroups with and without the MS ([Table 2](#t2-dmso-12-043){ref-type="table"}).

Comparison of HD group and C group with and without the MS
----------------------------------------------------------

HD-MS subgroup, compared to C-MS subgroup, showed significantly higher serum concentrations of RES (36.26±14.47 vs 6.81±2.19 ng/mL; *P*\<0.001), cystatin C (6,720±2,273 vs 2,032±1,034 ng/mL; *P*\<0.001), hs-CRP (9.26±9.62 vs 1.50±1.39 mg/L; *P*\<0.001), TNF-α (22.08±11.46 vs 9.22±2.55 pg/mL; *P*\<0.001), Hcy (22.00±10.03 vs 13.64±2.55 µmol/L; *P*=0.001), phosphorus (5.55±1.00 vs 4.06±0.61 mg/dL; *P*\<0.001), PTH (261.5±210.6 vs 52.14±21.50 pg/mL; *P*=0.001). Similar differences were demonstrated between HD-nMS patients and C-nMS subgroup, that is, elevated RES (30.16±11.04 vs 5.98±3.45 ng/ mL; *P*\<0.001), cystatin C (6031±1,653 vs 1,604±581 ng/mL; *P*\<0.001), hs-CRP (5.49±5.68 vs 0.87±0.82 mg/L; *P*\<0.001), TNF-α (18.39±12.07 vs 6.70±2.17 pg/mL; *P*\<0.001), Hcy (20.98±5.46 vs 12.55±3.95; *P*\<0.001), phosphorus (4.92±1.45 vs 3.87±0.68 mg/dL; *P*\<0.001), PTH (158.7±152.2 vs 57.92±28.40 pg/mL; *P*=0.01). Serum leptin concentration was significantly higher in HD-MS patients compared to C-MS subgroup (40.23±31.99 vs 14.78±13.17 ng/mL; *P*=0.01) while no significant differences were found between HD-nMS vs C-nMS. Total white cell and lymphocyte counts were significantly higher in HD-nMS patients compared to C-nMS subgroup (7.21±1.71 vs 5.31±1.23×10³/µL; *P*=0.002 and 1.80±0.48 vs 1.32±0.37×10³/µL; *P*=0.02, respectively). Irrespective of the presence or absence of the MS, serum albumin concentrations were lower in HD group compared to group C (41.40±5.12 vs 48.02±2.53 g/L; *P*\<0.001 and 39.61±6.68 vs 47.55±3.70 g/L; *P*\<0.001, respectively). Other study parameters did not differ significantly between dialyzed patients and individuals with normal renal function ([Table 2](#t2-dmso-12-043){ref-type="table"}).

Effect of rehabilitation program on the study parameters
--------------------------------------------------------

As compared to pre-exercise levels, elevation of serum RES was observed in HD-nMS patients at the day next to the program completion (30.16±11.04 vs 34.22±8.89 ng/mL; *P*=0.046) while no change was observed in HD-MS patients. Serum RES remained unchanged in the C-nMS subgroup while non-significant reduction (6.81±2.19 vs 6.26±1.91 ng/ mL; *P*=0.07) in C-MS individuals was observed. Non-significant reduction of cystatin C concentrations (6,720±2,273 vs 5,780±2,054 ng/mL; *P*=0.098) and elevation of insulin concentrations (12.55±5.95 vs 18.10±8.88 µIU/mL; *P*=0.049) in HD-MS patients was observed ([Table 3](#t3-dmso-12-043){ref-type="table"}).

Post-intervention changes in the concentrations of other cytokines and hormones in the HD and C groups did not reach the level of statistical significance.

RES correlations
----------------

### Correlation between RES and albumin concentrations

HD group showed correlation between serum albumin and RES concentrations. Pre-exercise correlation was statistically significant in HD-MS patients (*R*=0.58; *P*=0.03) and non-significant in HD-nMS patients (*R*=0.49; *P*=0.07). Following the 4-week program of regular physical exercise, the correlation in HD-MS patients was no longer statistically significant (*R*=0.26; *P*=0.37) while the correlation between RES and albumin became significant in HD-nMS patients (*R*=0.69; *P*=0.007). Group C demonstrated no correlation between serum albumin and RES concentrations, regardless of the presence or absence of the MS ([Figures 2](#f2-dmso-12-043){ref-type="fig"} and [3](#f3-dmso-12-043){ref-type="fig"}).

Correlation between RES and insulin concentrations and HOMA-IR
--------------------------------------------------------------

Before the program, HD-nMS patients showed a significant negative correlation between RES and insulin concentrations (R=−0.66; *P*=0.01) as well as between RES and HOMA-IR (R=−0.68; *P*=0.007). After the completion of the rehabilitation program, no significant correlations were noted between RES and insulin or HOMA-IR in HD-nMS patients ([Table 4](#t4-dmso-12-043){ref-type="table"}).

No significant pre- or post-rehabilitation program correlations were found in HD-MS patients and group C.

### Other correlations

In HD-MS, the pre-rehabilitation program positive correlation between RES and leptin concentrations was non-significant (*R*=0.49; *P*=0.07) while the correlation between RES and IL-6 was significant (*R*=0.62; *P*=0.02). The same group also showed significant positive correlations between RES and the leukocyte (*R*=0.70; *P*=0.007) and lymphocyte (*R*=0.77; *P*=0.002) counts as well as between RES and phosphorous concentration (*R*=0.68; *P*=0.007) ([Table 4](#t4-dmso-12-043){ref-type="table"}).

Following the rehabilitation program, HD-MS patients still showed a positive and significant correlation between RES and IL-6 concentrations (*R*=0.61; *P*=0.02) and the leukocyte count (*R*=0.61; *P*=0.02) while correlation between RES and the lymphocyte count and phosphorous was no longer significant.

No significant correlations were observed between these parameters in HD-nMS.

Negative correlation between RES and PTH concentrations was observed in HD-MS patients before the exercise program (R=−0.65; *P*=0.01). No such correlation was revealed following the completion of the program.

HD-nMS patients showed negative significant correlation between RES and PAI-1 concentrations after physical exercise program (R=−0.55; *P*=0.04). No correlation between serum RES and these parameters was observed before and after physical exercise in HD-MS subgroup.

C-nMS participants showed a positive pre-rehabilitation program correlation between serum RES and the leukocyte count (*R*=0.54; *P*=0.02) as well as between RES and IL-6 (*R*=0.56; *P*=0.04). In the C-nMS subgroup, a positive correlation was observed between RES and TNF-α concentrations (*R*=0.51; *P*=0.04) post-rehabilitation program. Other correlations were not significant.

Discussion
==========

This study is the first one to evaluate the influence of a supervised rehabilitation program on a range of serum hormones and cytokines including RES in HD patients with respect to the diagnosis of MS. Our results confirm previous observations[@b2-dmso-12-043],[@b6-dmso-12-043],[@b7-dmso-12-043] that uremic patients have elevated concentrations of this adipokine. The MS had no significant impact on RES concentrations in individuals with normal renal function and those with renal failure. However, we found an unexpected RES increase in dialyzed patients without the MS following 4-week rehabilitation program, contrary to dialyzed patients with MS and to the control group. Apart from the fact that it needs confirmation in further studies and that it could be a result of a pre-analytical or laboratory error, a possible explanation of this observation would be expected. It has been demonstrated that contracting muscles increase the production of IL-6 and, in consequence, its concentration in the serum.[@b40-dmso-12-043],[@b41-dmso-12-043] On the other hand, it was observed that IL-6 can stimulate the secretion of RES.[@b42-dmso-12-043] In our study, we observed a non-significant IL-6 concentrations increase after physical exercise in HD-MS patients and HD-nMS patients and we also observed significant correlations between IL-6 and RES (only in patients with the MS). In patients without the MS, there is only a tendency for such correlation after physical exercise program. Therefore, it cannot be excluded that the observed RES increase immediately after completion of the rehabilitation program was associated with the influence of IL-6 on RES production in patients with diminished clearance of these cytokines which are poorly removed during hemodialysis. Unfortunately, we were unable to determine a delayed effect of the rehabilitation program on the RES concentration. RES elevation following the rehabilitation program in dialyzed patients may not be considered explicit unfavorable due to the phenomenon of reverse epidemiology in the dialyzed patients. A hypothesis suggesting a favorable change might be supported by a positive correlation between RES and albumin concentrations and negative correlation between concentrations of RES and plasminogen activator (PAI-1). Albumin concentration is an important index of nutritional status, a negative inflammatory marker, and one of the major negative predictors of mortality in dialyzed patients. Hence, it might suggest that changes in RES concentrations parallel to albumin concentration change reflect beneficial metabolic effect. However, this assumption is contrary to observations of Kaynar et al[@b43-dmso-12-043] who demonstrated positive correlation between the degree of protein-energy malnutrition and RES and adiponectin concentrations. On the other hand, a hypothesis suggesting beneficial effect of serum RES elevation in HD-nMS patients seems to be supported by a negative correlation between concentrations of this cytokine and PAI-1 which is a well-defined cardiovascular risk factor.[@b44-dmso-12-043] The correlations specified above allow no explicit definition of a cause--effect relationship between the study parameters as they merely indicate the existence of some relationship. A suggestion that RES elevation might have beneficial effects has been rejected by other authors[@b32-dmso-12-043] who demonstrated a decrease in serum RES in individuals with normal renal function after exercise training intervention. The present study failed to confirm such relationship which might have been caused by a small study sample. The physiological and pathophysiological roles of RES remain unclear. Numerous authors have emphasized its association with the inflammatory condition.[@b45-dmso-12-043]--[@b47-dmso-12-043] However, only few studies demonstrated a direct relationship between RES concentrations and clinical manifestations of inflammation. Some reports indicate that both high and low RES concentrations were predictors of frequent hospitalization. There are some reports indicating that low RES concentrations are associated with the need for more frequent hospitalization of HD patients. Thus, this relationship may not be linear but U-shaped.[@b48-dmso-12-043] Spoto et al observed that the effect of RES on cardiovascular risk was modified by adiponectin concentration.[@b49-dmso-12-043] Studies of the role of RES have also shown that old age and serum concentration of this adipokine exceeding 127.4 ng/mL were independent risk factors for death in HD patients.[@b50-dmso-12-043] Also some studies suggest a beneficial effect of RES in individuals with normal renal function. It was observed that serum RES concentrations were significantly lower in neonates with intrauterine infection compared to healthy neonates (17.8 vs 27 ng/mL). The differences did not depend on sex, type of delivery, or general condition of a neonate after birth.[@b51-dmso-12-043] Other studies showed a negative correlation between RES concentration and BNP and NT-proBNP concentrations.[@b52-dmso-12-043] Most probably, there are multiple mechanisms underlying RES synthesis and effects.

Our findings allow no explicit conclusions and should be considered with caution. We are unable to determine the clinical significance of the study. Further research with a larger research sample is needed. This is the first study on the impact of exercise training intervention on RES concentration in HD patients.

None of the previous publications reported significant reduction of proinflammatory cytokines, for example, CRP, IL-6, TNF-α, after physical activity programs[@b27-dmso-12-043],[@b31-dmso-12-043],[@b53-dmso-12-043] in HD patients. We also did not observe such a relationship although cystatin C reduction in HD-MS patients approached statistical significance. We believe this is the first one comprising an inpatient rehabilitation program, where exercise was taken daily under specialist supervision. Physical effort was meticulously controlled and all the participants completed 90%--100% of the individually tailored physical exercise program. So far, investigations of physical effort of HD patients concerned exercise taken twice or three times a week for 15--60 minutes during first 2 hours of hemodialysis session,[@b54-dmso-12-043]--[@b57-dmso-12-043] ambulatory rehabilitation programs,[@b56-dmso-12-043] or exercises done by the patient at home.[@b57-dmso-12-043]--[@b60-dmso-12-043] Observation period usually wasted 1 to 24 months[@b54-dmso-12-043],[@b57-dmso-12-043],[@b61-dmso-12-043],[@b62-dmso-12-043] or longer.[@b63-dmso-12-043],[@b64-dmso-12-043] Previous studies of the effect of physical effort in HD patients focused on effort tolerance, ability to walk, muscular strength, quality of life, quality of sleep, and the restless feet syndrome.[@b65-dmso-12-043]--[@b67-dmso-12-043] Only few contributions addressed the question of the effect of physical activity on cardiovascular risk[@b47-dmso-12-043],[@b68-dmso-12-043],[@b69-dmso-12-043] and dialysis efficiency[@b70-dmso-12-043] in HD patients. Compared to individuals with normal renal function, our study showed RES elevation as well as higher concentrations of cystatin C, hs-CRP, TNF-α, homocystein, and PTH. These results are supported by other authors, suggesting that elevated RES, cystatin C, hs-CRP, and TNF-α concentrations in HD patients are most probably the consequence of inflammatory condition and reduced elimination of cytokines due to renal failure.[@b71-dmso-12-043] The MS was associated with significantly higher leptin concentrations. In HD patients with the MS, higher leptin concentrations were associated with impaired renal function. In HD patients without the MS, renal function did not seem to have a marked effect on leptin concentrations.

Another unexpected observation was an increase of insulin concentration (12.55±5.95 vs 18.10±8.88 µIU/mL; *P*=0.049) after the rehabilitation program in HD patients with MS. Initially insulin concentrations were higher in control group compared to dialyzed patients. Therefore, exercise training intervention could increase synthesis and release of insulin. Also, one might speculate that higher insulin levels was due to decreased insulin clearance in end stage renal disease.[@b72-dmso-12-043] On the other hand, it is known[@b73-dmso-12-043] that excessive physical exercise may lead to counter-regulatory hyperglycemia. It is possible that despite being careful, the exercises applied in HD patients with the MS were too strenuous for them. In the present study, higher RES concentrations were not associated with insulin resistance. A negative correlation between RES and insulin concentrations as well as HOMA-IR index in the subgroup of HD patients without the MS prior to the rehabilitation program was observed. However, results of other studies do not allow unequivocal definition of the relationship between RES and insulin resistance. No correlation between RES concentrations and insulin resistance was observed in non-obese patients on peritoneal dialysis.[@b74-dmso-12-043] On the other hand, in an extensive Finnish cross-sectional health examination survey, RES turned out to be an independent predictor of the MS and correlated with insulin resistance.[@b75-dmso-12-043] The MS in our HD patients and individuals with normal renal function was associated with higher leptin concentrations. Other authors confirmed this observation.[@b45-dmso-12-043] PAI-1 concentration was higher in HD patients with the MS compared to HD patients without the MS, while individuals with normal renal function and the MS showed a significant increase in TNF-α concentrations compared to individuals with normal renal function without the MS.

Strength and limitations
========================

There are several limitations of this study. First, it comprised a relatively small number of participants what was a result of a complex method. Second, the observation period was relatively short. However, the authors' focus was to evaluate the effect of daily physical exercise performed by inpatient under close supervision. The third limitation stems from the fact that our study only comprised patients of a single dialysis center, which however facilitated the elimination of confounding factors associated with different standards and procedures.

Strength of our study was the daily scheme of individually tailored exercises, in inpatient conditions ensuring permanent supervision by an interdisciplinary team that resulted in very high compliance. So far, such a scheme has never been undertaken in HD patients. Another advantage was that all measurements and laboratory tests were performed using the same methods and by the same research team.

The added value of this study was an implementation of the regular physical activity habit in our patients.

Conclusion
==========

A metabolic and inflammatory response for the 4-week supervised rehabilitation program is changed in end-stage renal disease HD patients as compared to controls with normal renal function. MS modifies a RES response to the rehabilitation program in HD patients. An increase of RES concentration in HD patients without the MS immediately after completion of the rehabilitation program needs further exploration.
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**Notes:** (**A**) individuals with normal renal function before rehabilitation program, (**B**) individuals with normal renal function after rehabilitation program, (**C**) individuals with normal renal function without the metabolic syndrome before rehabilitation program, (**D**) individuals with normal renal function without the metabolic syndrome after rehabilitation program, (**E**) individuals with normal renal function and the metabolic syndrome before rehabilitation program, (**F**) individuals with normal renal function and the metabolic syndrome after rehabilitation program.\
**Abbreviations:** C, control group; MS, metabolic syndrome; nMS, non-metabolic syndrome.](dmso-12-043Fig3){#f3-dmso-12-043}

###### 

Baseline characteristics of the patients participating in the study (n=58)

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                                               Study group (HD) n=28          Control group (C) n=30        *P*-value
  ----------------------------------------------------------------------- ------------------------------ ----------------------------- -----------
  Age (years, $\overline{x} \pm \text{SD}$)                               56.9±13.3 (range 25--75)       61.5±8.3 (range 37--76)       0.12

  Sex, n (%) female/male                                                  16 (57)/12 (43)                15 (50)/15 (50)               0.61

  Dialysis vintage (months, $\overline{x} \pm \text{SD}$)                 50.6±73.4 (range 5--272)       --                            

  Frequency of dialysis, n (%)\                                           24 (85.7)\                     --                            
  3 times per week\                                                       3 (10.7)\                                                    
  4 times per week\                                                       1 (3.6)                                                      
  5 times per week                                                                                                                     

  Dialysis adequacy (Kt/V)                                                1.41±0.23                      --                            

  BMI (kg/m^2^, $\overline{x} \pm \text{SD}$                              27.1±6.08 (range 16.4--42.1)   29.2±5.3 (range 21.3--41.0)   0.16

  Weight (kg, $\overline{x} \pm \text{SD}$)                               74.1±20.1 (range 43--126)      79.9±17.7 (range 53--117)     0.25

  Waist circumference (cm, $\overline{x} \pm \text{SD}$)                  96.3±17.0 (range 72--126)      96.7±13.4 (range 77--129)     0.92

  Vascular access, n (%)\                                                 24 (85.6)\                     --                            
   Arteriovenous fistulas\                                                2 (7.2)\                                                     
   Arteriovenous grafts\                                                  2 (7.2)                                                      
   Central venous catheters                                                                                                            

  Cause of end-stage renal disease, n(%)\                                 7 (25.1)\                      --                            
   Glomerulonephritis\                                                    6 (21.4)\                                                    
   Diabetic renal disease\                                                6 (21.4)\                                                    
   Hypertension nephropathy\                                              9 (32.1)                                                     
   Others                                                                                                                              

  Charlson comorbidity index (CCI, point, $\overline{x} \pm \text{SD}$)   4.5±3.6 (range 2--13)          1.03±0.61(range 0--2)         \<0.001

  Metabolic syndrome, n (%)                                               14 (50)                        13 (43.3)                     0.79

  Diabetes, n (%)                                                         7 (25)                         4 (14.3)                      0.32

  Estimated GFR (mL/min/1.73 m^2^)                                        8.6±4.9                        85.6±15.9                     \<0.001

  PVo~2~, (mL/kg/min)                                                     17.5±4.1                       21.2±5.2                      0.018

  Hemoglobin (g/dL)                                                       11.16±1.34                     13.85±0.81                    \<0.001

  Glucose (mg/dL)                                                         96.3±34.4                      113.5±37.5                    0.002

  Creatinine (mg/dL)                                                      6.75±2.43                      0.84±0.16                     \<0.001

  Sodium (mmol/dL)                                                        139.6±2.9                      139.4±2.0                     0.70

  Potassium (mmol/dL)                                                     5.23±0.52                      4.74±0.43                     \<0.001

  Resistin (ng/mL)                                                        33.21±13.00                    6.34±2.95                     \<0.001

  Leptin (ng/mL)                                                          29.91±33.00                    10.99±11.40                   0.02

  Adiponectin (µg/mL)                                                     25.42±18.40                    21.37±10.21                   0.89

  Cystatin C (ng/mL)                                                      6375±1981                      1789±821                      \<0.001

  Erythropoietin (mIU/mL)                                                 21.44±27.10                    10.67±8.92                    0.20

  hs-CRP (mg/L)                                                           7.37±7.99                      1.14±1.13                     \<0.001

  TNF-α (pg/mL)                                                           20.23±11.70                    7.79±2.62                     0.001

  IL-6 (pg/mL)                                                            8.55±7.56                      9.68±5.15                     0.31

  TGF-β1 (pg/mL)                                                          317.2±126.8                    373.5±163.2                   0.32

  PAI-1 (ng/mL)                                                           43.44±22.74                    51.43±49.72                   0.74

  Hcy (µmol/L)                                                            21.49±7.94                     13.02±3.41                    \<0.001

  WBC (×10³/µL)                                                           6.93±1.92                      5.98±2.00                     0.02

  Lymphocyte (×10³/µL)                                                    1.69±0.50                      1.50±0.47                     0.08

  Insulin[a](#tfn2-dmso-12-043){ref-type="table-fn"} (µIU/mL)             11.02±6.74                     12.52±7.08                    0.53

  HbA1c (%)                                                               6.19±1.55                      6.39±1.34                     0.56

  Albumin (g/L)                                                           40.51±5.91                     47.75±3.21                    \<0.001

  Phosphorus (inorganic) (mg/dL)                                          5.23±1.26                      3.95±0.65                     \<0.001

  PTH (pg/mL)                                                             210.1±187.8                    55.41±25.39                   \<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** Results are mean ± SD or percentage; significant at *P*-value \<0.05;

six patients treated with insulin were excluded.

**Abbreviations:** BMI, body mass index; GFR, glomerular filtration rate; HbA1c, glycated hemoglobin; Hcy, homocysteine; IL-6, interleukin-6; PAI-1, plasminogen activator inhibitor-1; PTH, parathyroid hormone; PVo~2~, peak oxygen uptake; TGF-β1, transforming growth factor beta 1; TNF-α, tumor necrosis factor alpha; WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein.

###### 

Baseline comparison the biochemical markers in the study group (HD) and control group (C) with the metabolic syndrome (MS) and without the metabolic syndrome (nMS)

  Biochemical markers                                           Study group (HD)   Control group (C)   *P*-value HD vs C                           
  ------------------------------------------------------------- ------------------ ------------------- ------------------- ------------- --------- ---------
                                                                                                                                                   
  Resistin (ng/mL)                                              36.26±14.47        30.16±11.04         6.81±2.19           5.98±3.45     \<0.001   \<0.001
  *P*=0.12                                                                         *P*=0.23                                                        
  Leptin (ng/mL)                                                40.23±31.99        19.60±31.78         14.78±13.17         8.10±9.22     0.01      0.28
  *P*=0.01                                                                         *P*=0.04                                                        
  Adiponectin (µg/mL)                                           18.15±9.95         28.78±19.29         20.64±10.19         21.92±10.51   0.38      0.40
  *P*=0.07                                                                         *P*=0.74                                                        
  Cystatin C (ng/mL)                                            6720±2273          6031±1653           2032±1034           1604±581      \<0.001   \<0.001
  *P*=0.37                                                                         *P*=0.37                                                        
  Erythropoietin (mIU/mL)                                       11.74±9.96         31.15±34.97         11.06±9.57          10.36±8.68    0.98      0.09
  *P*=0.20                                                                         *P*=0.90                                                        
  hs-CRP (mg/L)                                                 9.26±9.62          5.49±5.68           1.50±1.39           0.87±0.82     \<0.001   \<0.001
  *P*=0.32                                                                         *P*=0.35                                                        
  TNF-α (pg/mL)                                                 22.08±11.46        18.39±12.07         9.22±2.55           6.70±2.17     \<0.001   \<0.001
  *P*=0.41                                                                         *P*=0.007                                                       
  IL-6 (pg/mL)                                                  9.93±7.35          7.17±7.78           9.03±4.17           10.33±6.08    0.79      0.13
  *P*=0.22                                                                         *P*=0.71                                                        
  TGF-β1 (pg/mL)                                                346.2±137.8        288.2±112.2         374.3±166.6         372.9±165.7   0.87      0.21
  *P*=0.23                                                                         *P*=0.90                                                        
  PAI-1 (ng/mL)                                                 52.24±24.14        34.63±18.01         72.95±65.82         34.97±23.83   0.72      0.89
  *P*=0.04                                                                         *P*=0.24                                                        
  Hcy (µmol/L)                                                  22.00±10.03        20.98±5.46          13.64±2.55          12.55±3.95    \<0.001   \<0.001
  *P*=0.77                                                                         *P*=0.39                                                        
  WBC (×10³/µL)                                                 6.65±2.14          7.21±1.71           6.93±2.51           5.31±1.23     0.90      0.002
  *P*=0.29                                                                         *P*=0.03                                                        
  Lymphocyte (×10³/µL)                                          1.62±0.51          1.80±0.48           1.74±0.49           1.32±0.37     0.80      0.02
  *P*=0.33                                                                         *P*=0.24                                                        
  Insulin[a](#tfn5-dmso-12-043){ref-type="table-fn"} (µIU/mL)   12.55±5.95         10.16±7.22          17.43±11.13         10.85±7.11    0.28      0.75
  *P*=0.46                                                                         *P*=0.62                                                        
  HbA1c (%)                                                     6.19±1.55          4.97±0.80           6.39±1.34           5.37±0.75     0.56      0.16
  *P*=0.01                                                                         *P*=0.02                                                        
  Albumin (g/L)                                                 41.40±5.12         39.61±6.68          48.02±2.53          47.55±3.70    \<0.001   \<0.001
  *P*=0.35                                                                         *P*=0.69                                                        
  Phosphorus (inorganic) (mg/dL)                                5.55±1.00          4.92±1.45           4.06±0.61           3.87±0.68     \<0.001   \<0.001
  *P*=0.049                                                                        *P*=0.62                                                        
  PTH (pg/mL)                                                   261.5±210.6        158.7±152.2         52.14±21.50         57.92±28.40   0.001     0.01
  *P*=0.33                                                                         *P*=0.55                                                        

**Note:** Results are mean ± SD; significant at *P*-value \<0.05;

six patients treated with insulin were excluded.

**Abbreviations:** HbA1c, glycated hemoglobin; Hcy, homocysteine; IL-6, interleukin-6; nMS, non-metabolic syndrome; PAI-1, plasminogen activator inhibitor-1; PTH, parathyroid hormone; TGF-β1, transforming growth factor beta 1; TNF-α, tumor necrosis factor alpha; WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein.

###### 

Comparison of the biochemical markers before and after the rehabilitation program

  Biochemical markers                                           Study group (HD) with the metabolic syndrome (subgroup HD-MS)   Study group (HD) without the metabolic syndrome (subgroup HD-nMS)   Control group (C) with the metabolic syndrome (subgroup C-MS)   Control group (C) without the metabolic syndrome (subgroup C-nMS)                                             
  ------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------- ------------- ------------- ------------- -------------
                                                                                                                                                                                                                                                                                                                                                                                  
  Resistin (ng/mL)                                              36.26±14.47                                                     36.48±14.58                                                         30.16±11.04                                                     34.22±8.89                                                          6.81±2.19     6.26±1.91     5.98±3.45     5.87±2.30
  *P*=0.44                                                                                                                      *P*=0.046                                                                                                                           *P*=0.07                                                                          *P*=0.91                    
  Leptin (ng/mL)                                                40.23±31.99                                                     36.01±32.97                                                         19.60±31.78                                                     22.06±29.38                                                         14.78±13.17   14.12±13.27   8.10±9.22     9.67±11.78
  *P*=0.36                                                                                                                      *P*=0.22                                                                                                                            *P*=0.62                                                                          *P*=0.36                    
  Adiponectin (µg/mL)                                           18.15±9.95                                                      23.52±20.45                                                         28.78±19.29                                                     27.65±18.93                                                         20.64±10.19   19.59±8.69    21.92±10.51   20.48±12.73
  *P*=0.51                                                                                                                      *P*=0.55                                                                                                                            *P*=0.86                                                                          *P*=0.38                    
  Cystatin C (ng/mL)                                            6720±2273                                                       5780±2054                                                           6031±1653                                                       6274±1822                                                           2032±1034     1872±735      1604±581      1653±420
  *P*=0.098                                                                                                                     *P*=0.42^.^                                                                                                                         *P*=0.35                                                                          *P*=0.25                    
  Erythropoietin (mIU/mL)                                       11.74±9.96                                                      13.17±11.02                                                         31.15±34.97                                                     19.55±20.52                                                         11.06±9.57    11.75±8.27    10.36±8.68    9.36±9.55
  *P*=0.78                                                                                                                      *P*=0.46                                                                                                                            *P*=0.42                                                                          *P*=0.31                    
  hs-CRP (mg/L)                                                 9.26±9.62                                                       10.84±9.26                                                          5.49±5.68                                                       6.29±8.90                                                           1.50±1.39     1.58±1.25     0.87±0.82     1.08±1.25
  *P*=0.81                                                                                                                      *P*=0.97                                                                                                                            *P*=0.97^.^                                                                       *P*=0.65^.^                 
  TNF-α (pg/mL)                                                 22.08±11.46                                                     18.86±12.51                                                         18.39±12.07                                                     19.34±12.02                                                         9.22±2.55     8.64±3.11     6.70±2.17     6.22±2.41
  *P*=0.55^.^                                                                                                                   *P*=0.84^.^                                                                                                                         *P*=0.48^.^                                                                       *P*=0.25                    
  IL-6 (pg/mL)                                                  9.93±7.35                                                       15.26±22.12                                                         7.17±7.78                                                       14.22±30.50                                                         9.03±4.17     7.74±4.78     10.33±6.08    12.65±8.04
  *P*=0.64                                                                                                                      *P*=0.81                                                                                                                            *P*=0.31                                                                          *P*=0.42                    
  TGF-β1 (pg/mL)                                                346.2±137.8                                                     385.6±239.2                                                         288.2±112.2                                                     305.2±145.2                                                         374.3±166.6   461.7±193.5   372.9±165.7   390.4±155.2
  *P*=0.64                                                                                                                      *P*=0.97                                                                                                                            *P*=0.25                                                                          *P*=0.37                    
  PAI-1 (ng/mL)                                                 52.24±24.14                                                     53.80±43.75                                                         34.63±18.01                                                     33.19±18.78                                                         72.95±65.82   87.03±91.15   34.97±23.83   35.84±36.06
  *P*=0.97                                                                                                                      *P*=0.35                                                                                                                            *P*=0.55                                                                          *P*=0.91                    
  Hcy (µmol/L)                                                  22.00±10.03                                                     21.41±9.77                                                          20.98±5.46                                                      21.76±8.39                                                          13.64±2.55    14.05±2.84    12.55±3.95    12.22±3.43
  *P*=0.92                                                                                                                      *P*=0.70                                                                                                                            *P*=0.27                                                                          *P*=0.30                    
  WBC (×10³/µL)                                                 6.65±2.14                                                       6.72±1.62                                                           7.21±1.21                                                       6.76±1.69                                                           6.93±2.51     6.54±1.99     5.31±1.23     5.23±1.16
  *P*=0.59                                                                                                                      *P*=0.40                                                                                                                            *P*=0.15                                                                          *P*=0.88                    
  Lymphocyte (×10³/µL)                                          1.62±0.51                                                       1.88±0.65                                                           1.80±0.48                                                       1.54±0.68                                                           1.74±0.49     1.55±0.54     1.32±0.37     1.38±0.29
  *P*=0.26                                                                                                                      *P*=0.35                                                                                                                            *P*=0.06                                                                          *P*=0.37                    
  Insulin[a](#tfn8-dmso-12-043){ref-type="table-fn"} (µIU/mL)   12.55±5.95                                                      18.10±8.88                                                          10.16±7.22                                                      8.77±5.25                                                           17.43±11.13   18.40±9.93    10.85±7.11    11.12±6.39
  *P*=0.049                                                                                                                     *P*=0.92                                                                                                                            *P*=0.81                                                                          *P*=0.94                    
  HbA1c (%)                                                     6.19±1.55                                                       6.53±1.56                                                           4.97±0.80                                                       4.74±0.90                                                           6.39±1.34     6.38±1.30     5.37±0.75     5.42±0.88
  *P*=0.09                                                                                                                      *P*=0.23                                                                                                                            *P*=0.94                                                                          *P*=0.91                    
  Albumin (g/L)                                                 41.40±5.12                                                      40.27±5.42                                                          39.61±6.68                                                      40.08±4.19                                                          48.02±2.53    47.85±4.34    47.55±3.70    48.99±4.15
  *P*=0.33                                                                                                                      *P*=0.92                                                                                                                            *P*=0.58                                                                          *P*=0.39                    
  Phosphorus (inorganic) (mg/dL)                                5.55±1.00                                                       4.90±1.30                                                           4.916±1.449                                                     4.818±1.885                                                         4.06±0.62     4.17±0.81     3.87±0.68     3.84±0.57
  *P*=0.21                                                                                                                      *P*=0.73                                                                                                                            *P*=0.73                                                                          *P*=0.62                    
  PTH (pg/mL)                                                   261.5±210.6                                                     259.0±250.5                                                         158.7±152.2                                                     215.9±262.0                                                         52.14±21.50   51.88±16.61   57.92±28.40   62.84±36.67
  *P*=0.47                                                                                                                      *P*=0.75                                                                                                                            *P*=0.81                                                                          *P*=0.79                    

**Note:** Results are mean ± SD; significant at *P*-value \<0.05;

six patients treated with insulin were excluded.

**Abbreviations:** HbA1c, glycated hemoglobin; Hcy, homocysteine; IL-6, interleukin-6; nMS, non-metabolic syndrome; PAI-1, plasminogen activator inhibitor-1; PTH, parathyroid hormone; TGF-β1, transforming growth factor beta 1; TNF-α, tumor necrosis factor alpha; WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein.

###### 

Correlation between serum resistin and biochemical markers before and after the rehabilitation program

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Biochemical markers                                            Study group (HD) with the metabolic syndrome (HD-MS)   Study group (HD) subgroup without the metabolic syndrome (HD-nMS)   Control group (C) subgroup with the metabolic syndrome (C-MS)   Control group (C) subgroup without the metabolic syndrome (C-nMS)                                     
  -------------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------- ---------- ----------- ---------- ----------
  Leptin (ng/mL)                                                 R=0.49\                                                R=0.22\                                                             R=−0.18\                                                        R=−0.41\                                                            R=−0.23\   R=0.07\     R=−0.30\   R=0.17\
                                                                 *P*=0.07                                               *P*=0.45                                                            *P*=0.53                                                        *P*=0.15                                                            *P*=0.46   *P*=0.71    *P*=0.24   *P*=0.52

  Adiponectin (µg/mL)                                            R=0.24\                                                R=0.15\                                                             R=0.37\                                                         R=0.16\                                                             R=0.49\    R=−0.13\    R=0.04\    R=−0.25\
                                                                 *P*=0.43                                               *P*=0.63                                                            *P*=0.19                                                        *P*=0.59                                                            *P*=0.09   *P*=0.49    *P*=0.87   *P*=0.33

  Cystatin C (ng/mL)                                             R=0.42\                                                R=0.09\                                                             R=0.18\                                                         R=0.21\                                                             R=0.00\    R=0.07\     R=0.14\    R=0.00\
                                                                 *P*=0.13                                               *P*=0.77                                                            *P*=0.53                                                        *P*=0.46                                                            *P*=0.99   *P*=0.72    *P*=0.58   *P*=1.00

  Erythropoietin (mIU/mL)                                        R=−0.03\                                               R=0.02\                                                             R=−0.46\                                                        R=0.27\                                                             R=0.53\    R=−0.01\    R=−0.22\   R=−0.42\
                                                                 *P*=0.91                                               *P*=0.94                                                            *P*=0.10                                                        *P*=0.36                                                            *P*=0.06   *P*=0.94    *P*=0.40   *P*=0.10

  hs-CRP (mg/L)                                                  R=−0.17\                                               R=0.12\                                                             R=0.11\                                                         R=0.07\                                                             R=0.13\    R=0.08\     R=0.12\    R=0.08\
                                                                 *P*=0.56                                               *P*=0.68                                                            *P*=0.71                                                        *P*=0.82                                                            *P*=0.67   *P*=0.66    *P*=0.64   *P*=0.76

  TNF-α (pg/mL)                                                  R=−0.10\                                               R=0.16\                                                             R=0.05\                                                         R=−0.09\                                                            R=−0.03\   R=0.54\     R=0.26\    R=0.51\
                                                                 *P*=0.74                                               *P*=0.57                                                            *P*=0.88                                                        *P*=0.76                                                            *P*=0.93   *P*=0.057   *P*=0.31   *P*=0.04

  IL-6 (pg/mL)                                                   R=0.62\                                                R=0.61\                                                             R=0.26\                                                         R=0.46\                                                             R=−0.08\   R=0.07\     R=0.56\    R=−0.20\
                                                                 *P*=0.02                                               *P*=0.02                                                            *P*=0.37                                                        *P*=0.09                                                            *P*=0.80   *P*=0.71    *P*=0.04   *P*=0.49

  TGF-β1 (pg/mL)                                                 R=0.42\                                                R=0.51\                                                             R=−0.09\                                                        R=0.002\                                                            R=−0.25\   R=−0.41\    R=−0.09\   R=−0.26\
                                                                 *P*=0.14                                               *P*=0.06                                                            *P*=0.75                                                        *P*=0.99                                                            *P*=0.40   *P*=0.17    *P*=0.75   *P*=0.31

  PAI-1 (ng/mL)                                                  R=0.45\                                                R=−0.14\                                                            R=−0.42\                                                        R=−0.55\                                                            R=−0.38\   R=−0.27\    R\         R=−0.26\
                                                                 *P*=0.10                                               *P*=0.63                                                            *P*=0.13                                                        *P*=0.04                                                            *P*=0.19   *P*=0.37    =−0.24\    *P*=0.30
                                                                                                                                                                                                                                                                                                                                                       *P*=0.35   

  Hcy (µmol/L)                                                   R=−0.18\                                               R=−0.05\                                                            R=0.33\                                                         R=−0.39\                                                            R=0.21\    R=0.32\     R=0.33\    R=0.14\
                                                                 *P*=0.53                                               *P*=0.85                                                            *P*=0.25                                                        *P*=0.17                                                            *P*=0.49   *P*=0.29    *P*=0.25   *P*=0.59

  WBC (×10^3^/µL)                                                R=0.70\                                                R=0.61\                                                             R=−0.30\                                                        R=0.23\                                                             R=−0.02\   R=−0.03\    R=0.54\    R=0.30\
                                                                 *P*=0.007                                              *P*=0.02                                                            *P*=0.29                                                        *P*=0.44                                                            *P*=0.94   *P*=0.92    *P*=0.02   *P*=0.24

  Lymphocyte (×10^3^/µL)                                         R=0.77\                                                R=0.31\                                                             R=0.38\                                                         R=0.31\                                                             R=0.35\    R=0.16\     R=−0.05\   R=−0.16\
                                                                 *P*=0.002                                              *P*=0.13                                                            *P*=0.31                                                        *P*=0.54                                                            *P*=0.24   *P*=0.60    *P*=0.84   *P*=0.54

  Insulin[a](#tfn11-dmso-12-043){ref-type="table-fn"} (µIU/mL)   R=0.29\                                                R=0.14\                                                             R=−0.66\                                                        R=−0.40\                                                            R=−0.20\   R=0.22\     R=−0.12\   R=−0.22\
                                                                 *P*=0.49                                               *P*=0.74                                                            *P*=0.01                                                        *P*=0.16                                                            *P*=0.52   *P*=0.47    *P*=0.66   *P*=0.40

  HOMA-IR^a^(mmol/L×µU/mL)                                       R=0.52\                                                R=0.38\                                                             R=−0.68\                                                        R=−0.32\                                                            R=−0.33\   R=0.20\     R=0.17\    R=−0.21\
                                                                 *P*=0.18                                               *P*=0.35                                                            *P*=0.007                                                       *P*=0.29                                                            *P*=0.32   *P*=0.53    *P*=0.52   *P*=0.42

  HbA1c (%)                                                      R=0.19\                                                R=−0.04\                                                            R=0.14\                                                         R=−0.37\                                                            R=0.01\    R=0.02\     R=0.23\    R=−0.23\
                                                                 *P*=0.51                                               *P*=0.18                                                            *P*=0.63                                                        *P*=0.21                                                            *P*=0.95   *P*=0.95    *P*=0.36   *P*=0.37

  Phosphorus (inorganic) (mg/dL)                                 R=0.68\                                                R=−0.20\                                                            R=0.10\                                                         R=−0.23\                                                            R=0.52\    R=−0.30\    R=0.15\    R=−0.44\
                                                                 *P*=0.007                                              *P*=0.50                                                            *P*=0.72                                                        *P*=0.42                                                            *P*=0.07   *P*=0.32    *P*=0.57   *P*=0.07

  PTH (pg/mL)                                                    R=−0.65\                                               R=−0.01\                                                            R=0.51\                                                         R=−0.23\                                                            R=−0.09\   R=0.49\     R=−0.28\   R=0.15\
                                                                 *P*=0.01                                               *P*=0.95                                                            *P*=0.06                                                        *P*=0.43                                                            *P*=0.76   *P*=0.09    *P*=0.27   *P*=0.57
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** R, Spearman's rank correlation coefficient, significant at *P*-value \<0.05;

six patients treated with insulin were excluded.

**Abbreviations:** HOMA-IR, Homoeostatic model assessment index (\[plasma glucose level, mmol/L × plasma insulin level, µIU/mL\]/22.5); HbA1c, glycated hemoglobin; Hcy, homocysteine; IL-6, Interleukin-6; nMS, non-metabolic syndrome; PAI-1, plasminogen activator inhibitor-1; PTH, parathyroid hormone; TGF-β1, transforming growth factor beta 1; TNF-α, tumor necrosis factor alpha; WBC, white blood cell; hs-CRP, high-sensitivity C-reactive protein.
